

06 05 06

CASE 100-7664F



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV72727404745

Express Mail Label Number

June 2, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1616

WALTER PRIKOSZOVICH

Examiner: Webman, Edward J.

APPLICATION NO: 10/054,490

FILED: JANUARY 22, 2002

FOR: IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

PETITION PURSUANT TO 37 CFR §1.97(d)

Sir:

Consideration of the Information Disclosure Statement submitted concurrently herewith is requested. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 for payment of the fee for filing this petition.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.


Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852
Date: June 2, 2006


Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152

06/06/2006 CCHAU1 00000016 190134 10054490

02 FC:1464 130.00 DA



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 7272740474S</u> Express Mail Label Number	<u>JUNE 2, 2006</u> Date of Deposit

THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1616

WALTER PRIKOSZOVICH

Examiner: Webman, Edward J.

APPLICATION NO: 10/054,490

FILED: JANUARY 22, 2002

FOR: IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statements filed March 6, 2002, November 17, 2003, and August 17, 2004 and is being filed in accordance with 37 C.F.R. §1.97(d).

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

A petition pursuant to 37 C.F.R. §1.97(d) is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee required by 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(d).


An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge the above-mentioned \$180 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis.

Statement under 37 C.F.R. §1.97(e)(2)

I, the undersigned, hereby certify that no item of information in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152


Date: *June 2, 2006*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
100-7664F
APPLICATION NO.
10/054,490
APPLICANT
Walter Prikoszovich
FILING DATE
JANUARY 22, 2002

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	5,041,529	8/20/91	Shimoda et al.			
AB	5,585,460	12/17/96	Yamada et al.			
AC	4,683,288	7/28/87	Tanaka et al.			
AD	4,677,191	6/30/87	Tanaka et al.			
AE	4,677,231	6/30/87	Aoshima et al.			
AF	5,922,338	7/13/99	Brich et al.			
AG	4,960,866	10/2/90	Bendix et al.			
AH	4,810,775	3/7/89	Bendix et al.			
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 270 987	6/15/88	EP (English Equiv. is U.S. 4,960,866)			<input type="checkbox"/>	<input type="checkbox"/>
	AN	1 467 970	3/23/77	GB			<input type="checkbox"/>	<input type="checkbox"/>
	AO	0 181 621	5/21/86	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	0 283 925	9/28/88	EP (English Equiv. is U.S. 4,810,775)			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	2 145 422	3/27/85	GB			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	D. L. Wise (ed.), Biopolymeric Controlled Release Systems, Vol. I, pp. 8-11 (1984)
AS	
AT	

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
100-7664F
APPLICATION NO.
10/054,490
APPLICANT
Walter Prikoszovich
FILING DATE
JANUARY 22, 2002

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA					
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					
	BL					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	BM 0 172 636	2/26/86	EP			<input type="checkbox"/>	<input type="checkbox"/>
	BN 0 171 907	2/19/86	EP			<input type="checkbox"/>	<input type="checkbox"/>
	BO					<input type="checkbox"/>	<input type="checkbox"/>
	BP					<input type="checkbox"/>	<input type="checkbox"/>
	BQ					<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.